References
- Tinto H, Ouedraogo JB, Erhart A, Van Overmeir C, Dujardin JC, Van Marck E, et al. Relationship between the Pfcrt T76 and the Pfmdr-1 Y86 mutations in Plasmodium falciparum and in vitro/in vivo chloroquine resistance in Burkina Faso, West Africa. Infect Genet Evol. 2003; 3:287-92.10.1016/j.meegid.2003.08.00214636690
- Happi TC, Thomas SM, Gbotosho GO, Falade CO, Akinboye DO, Gerena L, et al. Point mutations in the pfcrt and pfmdr-1 genes of Plasmodium falciparum and clinical response to chloroquine, among malaria patients from Nigeria. Ann Trop Med Parasitol. 2003; 97:439-51.10.1179/00034980323500248912930607
- Dorsey G, Kamya MR, Singh A, Rosenthal PJ. Polymorphisms in the Plasmodium falciparum pfcrt and pfmdr-1 genes and clinical response to chloroquine in Kampala, Uganda. J Infect Dis. 2001; 183:1417-20.10.1086/31986511294677
- Price R, Robinson G, Brockman A, Cowman A, Krishna S. Assessment of pfmdr 1 gene copy number by tandem competitive polymerase chain reaction. Mol Biochem Parasitol. 1997; 85:161-9.10.1016/S0166-6851(96)02822-89106190
- Duraisingh MT, Drakeley CJ, Muller O, Bailey R, Snounou G, Targett GA, et al. Evidence for selection for the tyrosine-86 allele of the pfmdr 1 gene of Plasmodium falciparum by chloroquine and amodiaquine. Parasitology. 1997; 114:205-11.10.1017/S00311820960084879075340
- Borrmann S, Adegnika AA, Missinou MA, Binder RK, Issifou S, Schindler A, et al. Short-course artesunate treatment of uncomplicated Plasmodium falciparum malaria in Gabon. Antimicrob Agents Chemother. 2003; 47:901-4.10.1128/AAC.47.3.901-904.200312604519
- Bunnag D, Viravan C, Looareesuwan S, Karbwang J, Harinasuta T. Double blind randomised clinical trial of oral artesunate at once or twice daily dose in falciparum malaria. Southeast Asian J Trop Med Public Health. 1991; 22:539-43.1820641
- Li GQ, Guo XB, Fu LC, Jian HX, Wang XH. Clinical trials of artemisinin and its derivatives in the treatment of malaria in China. Trans R Soc Trop Med Hyg. 1994; 88 Suppl 1:S5-6.8053027
- Ho M, Davis TM, Silamut K, Bunnag D, White NJ. Rosette formation of Plasmodium falciparum-infected erythrocytes from patients with acute malaria. Infect Immun. 1991; 59:2135-9.2037374
- Alin MH, Kihamia CM, Bjorkman A, Bwijo BA, Premji Z, Mtey GJ, et al. Efficacy of oral and intravenous artesunate in male Tanzanian adults with Plasmodium falciparum malaria and in vitro susceptibility to artemisinin, chloroquine, and mefloquine. Am J Trop Med Hyg. 1995; 53:639-45.10.4269/ajtmh.1995.53.6398561267
- Bunnag D, Viravan C, Looareesuwan S, Karbwang J, Harinasuta T. Double blind randomised clinical trial of two different regimens of oral artesunate in falciparum malaria. Southeast Asian J Trop Med Public Health. 1991; 22:534-8.1820640
- Anstey NM, Hassanali M Y, Mlalasi J, Manyenga D, Mwaikambo ED. Elevated levels of methaemoglobin in Tanzanian children with severe and uncomplicated malaria. Trans R Soc Trop Med Hyg. 1996; 90:147-51.876157510.1016/S0035-9203(96)90118-2
- Noedl H, Se Y, Schaecher K, Smith BL, Socheat D, Fukuda MM, et al. Evidence of artemisinin-resistant malaria in western Cambodia. N Engl J Med. 2008; 359: 2619-20.10.1056/NEJMc080501119064625
- Bethell D, Se Y, Lon C, Tyner S, Saunders D, Sriwichai S, et al. Artesunate dose escalation for the treatment of uncomplicated malaria in a region of reported artemisinin resistance: a randomized clinical trial. PLoS One. 2011; 6:e19283.10.1371/journal.pone.0019283
- Tyner SD, Lon C, Se Y, Bethell D, Socheat D, Noedl H, et al. Ex vivo drug sensitivity profiles of Plasmodium falciparum field isolates from Cambodia and Thailand, 2005 to 2010, determined by a histidine-rich protein-2 assay. Malar J. 2012; 11:198.10.1186/1475-2875-11-19822694953
- Saunders D, Khemawoot P, Vanachayangkul P, Siripokasupkul R, Bethell D, Tyner S, et al. Pharmacokinetics and pharmacodynamics of oral artesunate monotherapy in patients with uncomplicated Plasmodium falciparum malaria in western Cambodia. Antimicrob Agents Chemother. 2012; 56:5484-93.2286958110.1128/AAC.00044-12
- Krishna S, Kremsner PG. Artemisinin resistance needs to be defined rigorously to be understood: response to Dondorp and Ringwald. Trends Parasitol. 2013; 29: 361-2.2380986510.1016/j.pt.2013.05.006
- Krishna S, Kremsner PG. Antidogmatic approaches to artemisinin resistance: reappraisal as treatment failure with artemisinin combination therapy. Trends Parasitol. 2013; 29:313-7.10.1016/j.pt.2013.04.00123623760
- Eckstein-Ludwig U, Webb RJ, Van Goethem ID, East JM, Lee AG, Kimura M, et al. Artemisinins target the SERCA of Plasmodium falciparum. Nature. 2003; 424: 957-61.1293119210.1038/nature01813
- Pulcini S, Staines HM, Pittman JK, Slavic K, Doerig C, Halbert J, et al. Expression in yeast links field polymorphisms in PfATP6 to in vitro artemisinin resistance and identifies new inhibitor classes. J Infect Dis. 2013; 208:468-78.10.1093/infdis/jit17123599312
- Uhlemann AC, Krishna S. Antimalarial multi-drug resistance in Asia: mechanisms and assessment. Curr Top Microbiol Immunol. 2005; 295:39-53.16265886
- Uhlemann AC, Ramharter M, Lell B, Kremsner PG, Krishna S. Amplification of Plasmodium falciparum multidrug resistance gene 1 in isolates from Gabon. J Infect Dis. 2005; 192:1830-5.1623518510.1086/497337
- Uhlemann AC, Cameron A, Eckstein-Ludwig U, Fischbarg J, Iserovich P, Zuniga FA, et al. A single amino acid residue can determine the sensitivity of SERCAs to artemisinins. Nat Struct Mol Biol. 2005; 12: 628-9.1593749310.1038/nsmb947
- Jambou R, Legrand E, Niang M, Khim N, Lim P, Volney B, et al. Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6. Lancet. 2005; 366: 1960-3.1632569810.1016/S0140-6736(05)67787-2
- Ma H, Lewis D, Xu C, Inesi G, Toyoshima C. Functional and structural roles of critical amino acids within the “N”, “P”, and “A” domains of the Ca2+ ATPase (SERCA) headpiece. Biochemistry. 2005; 44:8090-100.10.1021/bi050332m
- Noedl H, Se Y, Sriwichai S, Schaecher K, Teja-Isavadharm P, Smith B, et al. Artemisinin resistance in Cambodia: a clinical trial designed to address an emerging problem in Southeast Asia. Clin Infect Dis. 2010; 51:e82-9.2102898510.1086/657120
- Price RN, Uhlemann AC, Brockman A, McGready R, Ashley E, Phaipun L, et al. Mefloquine resistance in Plasmodium falciparum and increased pfmdr1 gene copy number. Lancet. 2004; 364:438-47.10.1016/S0140-6736(04)16767-615288742
- Imwong M, Dondorp AM, Nosten F, Yi P, Mungthin M, Hanchana S, et al. Exploring the contribution of candidate genes to artemisinin resistance in Plasmodium falciparum. Antimicrob Agents Chemother. 2010; 54:2886-92.2042139510.1128/AAC.00032-10
- Miao M, Wang Z, Yang Z, Yuan L, Parker DM, Putaporntip C, et al. Genetic diversity and lack of artemisinin selection signature on the Plasmodium falciparum ATP6 in the Greater Mekong Subregion. PloS one. 2013; 8:e59192.10.1371/journal.pone.005919223555629
- Miotto O, Almagro-Garcia J, Manske M, Macinnis B, Campino S, Rockett KA, et al. Multiple populations of artemisinin-resistant Plasmodium falciparum in Cambodia. Nat Genet. 2013; 45:648-55.2362452710.1038/ng.2624
- Takala-Harrison S, Clark T G, Jacob C G, Cummings M P, Miotto O, Dondorp AM, et al. Genetic loci associated with delayed clearance of Plasmodium falciparum following artemisinin treatment in Southeast Asia. Proc Natl Acad Sci USA. 2013; 110:240-5.10.1073/pnas.1211205110
- Winzeler EA, Manary MJ. Drug resistance genomics of the antimalarial drug artemisinin. Genome Biol. 2014; 15:544.10.1186/s13059-014-0544-625470531
- Cardi D, Pozza A, Arnou B, Marchal E, Clausen JD, Andersen JP, et al. Purified E255L mutant SERCA1a and purified PfATP6 are sensitive to SERCA-type inhibitors but insensitive to artemisinins. J Biol Chem. 2010; 285:26406-16.10.1074/jbc.M109.09034020530490
- Cui L, Wang Z, Jiang H, Parker D, Wang H, Su XZ, et al. Lack of association of the S769N mutation in Plasmodium falciparum SERCA (PfATP6) with resistance to artemisinins. Antimicrob Agents Chemother. 2012; 56:2546-52.10.1128/AAC.05943-1122354307
- Valderramos SG, Scanfeld D, Uhlemann AC, Fidock DA, Krishna S. Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance. Antimicrob Agents Chemother. 2010; 54:3842-52.2056676210.1128/AAC.00121-10
- Abiodun OO, Brun R, Wittlin S. In vitro interaction of artemisinin derivatives or the fully synthetic peroxidic anti-malarial OZ277 with thapsigargin in Plasmodium falciparum strains. Malar J. 2013; 12:43.10.1186/1475-2875-12-4323368889
- Arnou B, Montigny C, Morth JP, Nissen P, Jaxel C, Moller J V, et al. The Plasmodium falciparum Ca2+-ATPase PfATP6: insensitive to artemisinin, but a potential drug target. Biochem Soc Trans. 2011; 39: 823-31.2159965510.1042/BST0390823
- Cojean S, Hubert V, Le Bras J, Durand R. Resistance to dihydroartemisinin. Emerg Infect Dis. 2006; 12: 1798-9.1728364510.3201/eid1211.060903
- Krishna S, Pulcini S, Fatih F, Staines H. Artemisinins and the biological basis for the PfATP6/SERCA hypothesis. Trends Parasitol. 2010; 26:517-23.2063890410.1016/j.pt.2010.06.014
- Afonso A, Hunt P, Cheesman S, Alves AC, Cunha CV, do Rosario V, et al. Malaria parasites can develop stable resistance to artemisinin but lack mutations in candidate genes atp6 (encoding the sarcoplasmic and endoplasmic reticulum Ca2+ ATPase), tctp, mdr1, and cg10. Antimicrob Agents Chemother. 2006; 50: 480-9.1643670010.1128/AAC.50.2.480-489.2006
- Bacon DJ, McCollum AM, Griffing SM, Salas C, Soberon V, Santolalla M, et al. Dynamics of malaria drug resistance patterns in the Amazon basin region following changes in Peruvian national treatment policy for uncomplicated malaria. Antimicrobial agents and chemotherapy. 2009; 53:2042-51.10.1128/AAC.01677-0819258269
- Tanabe K, Zakeri S, Palacpac NM, Afsharpad M, Randrianarivelojosia M, Kaneko A, et al. Spontaneous mutations in the Plasmodium falciparum sarcoplasmic/ endoplasmic reticulum Ca2+-ATPase (PfATP6) gene among geographically widespread parasite populations unexposed to artemisinin-based combination therapies. Antimicrob Agents Chemother. 2011; 55:94-100.2095659310.1128/AAC.01156-10
- Bhisutthibhan J, Pan XQ, Hossler PA, Walker DJ, Yowell CA, Carlton J, et al. The Plasmodium falciparum translationally controlled tumor protein homolog and its reaction with the antimalarial drug artemisinin. J Biol Chem. 1998; 273:16192-8.963267510.1074/jbc.273.26.16192